<DOC>
	<DOCNO>NCT02364076</DOCNO>
	<brief_summary>This non-randomized clinical trial patient thymic carcinoma fail prior systemic therapy . All subject receive MK-3475 treatment intravenously every three week unacceptable toxicity , death , progressive disease withdrawal .</brief_summary>
	<brief_title>MK-3475 Patients With Thymic Carcinoma</brief_title>
	<detailed_description>This phase II study MK-3475 thymic carcinoma patient least one prior chemotherapy regimen . Exploratory study perform archival tumor material ( PDL-1 expression , next-generation sequencing ) fresh biopsy ( culture , next-generation sequencing ) . Simon 's two-stage optimal design use . The null hypothesis true response rate 5 % test one-sided alternative . In first stage 9 subject accrue . If response 9 subject , study stop . Otherwise , 8 additional subject accrue total 17 . The null hypothesis reject 3 response see 17 subject .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologic confirmation thymic carcinoma Advanced disease amenable curative treatment At least 1 prior line chemotherapy Progression disease must document prior study entry Absence autoimmune syndrome typically associate thymomas thymic carcinoma ( myasthenia gravis , pure red cell aplasia ) Be willing able provide write informed consent trial Be 18 year age old day signing inform consent Have measurable disease base RECIST 1.1 Have provide tissue archival tissue sample newly obtain core excisional biopsy tumor lesion Have performance score 0 2 ECOG performance scale Demonstrate adequate organ function Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication Female subject childbearing potential willing avoid pregnancy course study 120 day last dose study medication . Male subject agree avoid conceive child start first dose study therapy 120 day last dose study therapy Has disease amenable radical treatment surgery radiation combination treatment Is currently participate participate study investigational agent use investigational device within 4 week first dose study treatment . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . Has prior monoclonal antibody within 4 week prior study Day 1 recover adverse event due agent administer 4 week earlier Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover adverse event due previously administer agent . Has know additional malignancy progress require active treatment Has know active central nervous system metastases and/or carcinomatous meningitis Has active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Has evidence interstitial lung disease active , noninfectious pneumonitis Has active infection require systemic therapy Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . Has know sensitivity pembrolizumab formulation Has know psychiatric substance abuse disorder would interfere requirement trial Is pregnant breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day trial treatment . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , anticytotoxic Tlymphocyteassociated antigen4 antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) Has know history Human Immunodeficiency Virus Has know active Hepatitis B Hepatitis C Has receive live vaccine within 30 day prior first dose trial treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>